Results 251 to 260 of about 651,817 (302)

A new perspective after facing the crucible of a Food and Drug Administration class 1 recall. [PDF]

J Clin Sleep Med
Lance CG, Hansen K.
europepmc   +1 more source

A Machine Learning Algorithm to Predict Medical Device Recall by the Food and Drug Administration. [PDF]

West J Emerg Med
Barbosa Slivinskis V, Agi Maluli I, Seth Broder J.   +2 more
europepmc   +1 more source

Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023). [PDF]

Eur J Cancer
Iannantuono GM, Floudas CS, Filetti M, Giovagnoli T, Sganga S, Vitale A, Chandran E, Lombardi P, Rosenfeld R, Giudice E, Xue E, Rapisarda E, Troisi P, Apolo AB, Karzai F, Bria E, Gulley JL, Daniele G.   +17 more
europepmc   +1 more source

Corrigendum to A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics. [PDF]

Perm J
europepmc   +1 more source

Response to "The Role of Patient- and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System". [PDF]

J Cosmet Dermatol
Zaminski D, Garshick M, Shapiro J, Sicco KL, Mazori DR.   +4 more
europepmc   +1 more source

Trust in the Food and Drug Administration: A National Survey Study. [PDF]

Clin Pharmacol Ther
Feldman WB, Rand LZ, Carpenter D, Russo M, Bhaskar A, Lu Z, Campbell EG, Darrow J, Kesselheim AS.   +8 more
europepmc   +1 more source

Safety assessment of dexmedetomidine: Real-world adverse event analysis from the Food and Drug Administration Adverse Events Reporting System public dashboard.

Indian J Pharmacol
Yin Y, Jiang J, Jin Y.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Food and Drug Administration Regulation

CNS Spectrums, 2008
As disease-modifying therapies near realization, there are concerns about the criteria by which these therapies will be judged. It is not yet clear what kind of evidence (clinical, biomarker, or otherwise) will be required to support a disease-modifying claim.
openaire   +2 more sources

Drug Development, Guidelines, and the Food and Drug Administration

Annals of Internal Medicine, 1984
Excerpt The costs of arthritis to society are climbing to an estimated $13.5 billion per year (1).
S H, Roth, A, Mackenzie
openaire   +2 more sources